Posted inComunicati
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE Nine-month findings show mean improvement in Composite Unified Huntington's Disease…









